GW VRU tests Pfizer's new vaccine for C. diff

Our director, Dr. David Diemert, recently interviewed with the Beacon Newspaper providing information on a new Pfizer study for C. diff, a bacterial infection that causes severe diarrhea. Click this link to get to the hompage: 

https://www.thebeaconnewspapers.com/

Check out the Washington Metro edition and the interview is on page 6!

 

Enrollment is still open for this study, you can find the link to the interest survey here:

https://redcap.link/gwvru-cdiff

 

Latest News

Dr. David Diemert, the director of the George Washington University Vaccine Research Unit, weighs in on President Donald Trump's executive order pushing for revisions to how children in the US are vaccinated and what that means for the future.
This was a phase 2, randomized, open-label, non-placebo controlled trial to evaluate two partial doses o the Modified Vaccinia Ankara-Bavarian Nordin (MVA-BN) vaccine for protection against mpox.
This was a phase 1, double-blind trial to examine the safety and immunogenicity of a replication-competent recombinant vesicular stomatitis virus-vectored vaccine to reduce the risk of infection and severe illness from Lassa Fever.